Lupus clinical trials at UC Irvine
6 in progress, 5 open to eligible people
FT819 in B-cell Mediated Autoimmune Disease
open to eligible people ages 12-70
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Irvine, California and other locations
Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
open to eligible people ages 12-100
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Irvine, California and other locations
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
open to eligible people ages 18-65
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Orange, California and other locations
Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
open to eligible people ages 18-100
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Orange, California and other locations
LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
open to eligible people ages 18-100
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Irvine, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
Sorry, not currently recruiting here
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Orange, California and other locations
Our lead scientists for Lupus research studies include Yongen Chang Priyanka Iyer, MD Sheetal Desai.
Last updated: